income 4,925 884 12,069 2,168
---------- --------- ---------- ---------
Net loss $ (51,910) $ (24,632) $ (124,140) $ (96,399)
========== ========= ========== =========
Net loss per share
attributable to
common
stockholders,
basic and diluted $ (2.75) $ (2.72) $ (7.21) $ (16.73)
========== ========= ========== =========
Weighted average
common shares
outstanding, basic
and diluted 18,884,562 9,039,427 17,210,604 5,763,121
========== ========= ========== =========
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576
(END) Dow Jones Newswires
November 06, 2024 07:30 ET (12:30 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.